A new coronavirus vaccine, which could provide long-lasting immunity and hopefully eradicate the deadly virus, is under way,media reported. Dozens of vaccine candidates are being developed around the world, two of which are already in human trials in the United States and China. In addition to acting as an enhanced immune response and producing antibodies to defeat the virus, the vaccine must also be safe. That’s why these vaccines can take at least 12 to 18 months to be ready for use.
But not all vaccines are injected with syringes, and researchers at the University of Pittsburgh School of Medicine have developed a vaccine that can enter the body with a finger-sized patch.
A few days ago, a study called Pitt CoVacc, short for Pittsburgh’s new coronavirus vaccine, was published in the Lancet journal EBioMedicine.
The target of the vaccine is an important part of the SARS-CoV-2 virus, the protoprotein. The researchers believe the vaccine will teach the body to use antibodies to respond to the protrusion protein, preventing the virus from entering the cells.
“We had SARS-CoV (SARS) and MERS-CoV (MERS-CoV) (MERS-CoV) in 2003 and 2014, respectively. These two viruses, which are closely related to SARS-CoV-2, tell us that a special protein, called a protoprotein, is important for inducing immunity to the virus. We know exactly where to fight this new virus,” said study co-author Dr. Andrea Gambotto, an associate professor of surgery at the University of Pittsburgh School of Medicine. You never know where the next epidemic will come from. “
The researchers made the virus protein in the lab and then fed the active ingredient into the skin by using a small piece containing 400 small needles made of sugar. This triggers a rapid immune system response, as both sugar and protrusion proteins dissolve into the skin.
“We developed this method based on scratch methods originally used to deliver smallpox vaccines to the skin, but as a high-tech version, it works more effectively and renewablely in patients,” says Professor Louis Falo, director of dermatology at Pitt Medical School. “
In addition to vaccine development, subsequent production is also important in the fight against the virus, and governments and pharmaceutical companies can easily increase production capacity so that it does not impede the spread and popularity of vaccines. That’s why Bill Gates says his foundation is working on no fewer than seven different vaccine candidates and creating a factory that will mass produce the final vaccine.
In response, researchers at PittCoVacc explained that their approach was highly scalable. This protein can be produced and purified on an industrial scale. It is understood that this patch can be placed at room temperature and does not need to be refrigerated during transport. In addition, the patch remains potent even after being disinfected with gamma rays, which is necessary for the human body before using the product.
The premise, of course, is that the vaccine is effective. As things stand, the results are promising, with PittCoVacc already producing effects in mice, which have produced a large number of SARS-CoV-2 antibodies within two weeks. But the researchers also needed to follow the subjects to see how long this immune effect lasted. In addition, they must wait for FDA approval for human trials, which are expected to begin in the coming months.